StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Janumet (sitagliptin and metformin HCl) by Year

Janumet (sitagliptin and metformin HCl) — U.S. sales ($M) ($M)

Merck Janumet (sitagliptin and metformin HCl): $268M in FY2025, up 66.5% from a year earlier.

Latest, FY2025
268
Period ended Dec 31, 2025
Change on a year earlier
+66.5%
161 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Janumet | 940 | 935 | 1 | 268 | 161 | 66 | 672 | 774 | -13”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up janumet (sitagliptin and metformin HCl)

Cite this data

StockData. (2026). Merck Janumet (sitagliptin and metformin HCl) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-janumet-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.